Everolimus, an inhibitor of mTOR, the central pathway involved in the pathophysiology of TSC, has been approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for patients with TSC-associated SEGA who require therapeutic intervention, but are not candidates for surgical resection (14). The gene discussed is MTOR; the disease is subependymal giant cell astrocytoma.